SB-T-1214 (SBT) is a taxane-based drug known for its ability to effectively suppress the expression of stem cell-related genes (Oct4, Sox2, and c-Myc) and induce apoptosis in drug-resistant tumorigenic CD133+/CD44+ colon cancer spheroids. In Pgp+ DLD-1 human colon tumor xenograft mouse models, SB-T-1214 successfully inhibits tumor growth. This compound is relevant for anti-tumor research, particularly against drug-resistant tumors such as colon, pancreatic, and renal cancers.

SB-T-1214, at concentrations ranging from 0.5 to 5000 nM over 72 hours, exhibits potent FR-specific anticancer activity, with IC50 values of 2.82 nM for ID8 cells, 1.89 nM for MX-1 cells, 2.66 nM for L1210-FR cells, and 4.89 nM for WI-38 cells. Additionally, when used at 0.1 to 1 μM over 48 hours, it induces apoptosis in colon cancer cells and spheres enriched in CSCs at 0.1 μM, resulting in the loss of integrity of floating spheres and generating 1.5-3% secondary spheres in HCT116, HT29, and DLD-1 cells. Furthermore, SB-T-1214 at 0.1 μM for 24-24 hours significantly downregulates most stemness genes, including SOX1, ACAN, and COL1A1, in CD133+/CD44+ spheroids of HCT116, HT29, and DLD-1 cells, and inhibits the protein expression of pluripotency markers Oct4, Sox2, and c-Myc.

SB-T-1214, administered at 10-40 mg/kg either via intraperitoneal or intravenous injection every three days for three doses (on days 5, 8, and 11), significantly inhibits tumor growth in a Pgp+ DLD-1 human colon cancer xenograft mouse model, demonstrating effective results at a dose of 20 mg/kg.